# Masimo Corporation (MASI) Growth Potential: Analyst Ratings Suggest a 26% Upside

- Link: https://www.directorstalkinterviews.com/masimo-corporation-masi-growth-potential-analyst-ratings-suggest-a-26-upside/4121213478
- Published: 2025-08-25T10:28:11+01:00
- Author: Madison Wilson

Masimo Corporation (NASDAQ: MASI) is a leading player in the healthcare sector, 
specializing in medical devices. Headquartered in Irvine, California, Masimo focuses
on developing and marketing advanced patient monitoring technologies and automation
solutions. With a market capitalization of $8.07 billion, the company continues 
to innovate and expand its reach both domestically and internationally.

Currently trading at $148.63, Masimo’s stock has experienced a modest price change
of $4.39, equivalent to a 0.03% increase. The 52-week trading range for MASI has
been between $111.36 and $190.63, reflecting some volatility but also potential 
for growth. Investors are keenly observing Masimo’s trajectory, especially in light
of the analyst ratings that signal a promising future.

The company’s forward price-to-earnings (P/E) ratio stands at 25.67, suggesting 
expectations of future earnings growth despite the absence of a trailing P/E ratio,
PEG ratio, and other valuation metrics. This points towards a company that is in
a transitional phase, focusing on growth and reinvestment rather than immediate 
profitability. This is further evidenced by the company’s revenue growth rate of
7.90%, which indicates a positive trajectory in expanding its market share and increasing
its sales.

However, Masimo’s financial performance is a mixed bag. The company reported an 
earnings per share (EPS) of -5.08, with a return on equity (ROE) of -22.37%. These
figures highlight challenges in profitability, which investors should weigh against
the company’s growth strategy and potential market opportunities. Notably, Masimo
maintains a healthy free cash flow of approximately $92.86 million, which provides
liquidity and the ability to fund future growth initiatives.

In terms of dividends, Masimo does not currently offer a dividend yield, with a 
payout ratio of 0.00%. This further underscores the company’s focus on reinvesting
profits to fuel innovation and expansion rather than returning capital to shareholders
in the form of dividends.

Analyst sentiment towards Masimo remains optimistic, with six buy ratings and two
hold ratings. Importantly, there are no sell ratings, indicating confidence in the
company’s strategic direction. The target price for MASI ranges from $170.00 to 
$210.00, with an average target of $187.57. This presents a potential upside of 
approximately 26.20% from the current trading price, making it an attractive option
for growth-oriented investors.

Technically, Masimo’s stock is trading below its 50-day and 200-day moving averages
of $159.11 and $165.01, respectively. The Relative Strength Index (RSI) is at 37.70,
which suggests that the stock may be approaching oversold territory, potentially
signaling a buying opportunity. The Moving Average Convergence Divergence (MACD)
is at -3.33, with a signal line at -3.08, indicating bearish momentum but also the
potential for a reversal.

Masimo’s comprehensive product offerings, spanning from pulse oximetry to hospital
automation and telehealth solutions, position it well in the evolving healthcare
landscape. The company’s direct sales force and extensive distribution network, 
along with partnerships with original equipment manufacturers, enable it to reach
a wide array of customers, including hospitals, emergency services, and home care
providers.

For investors considering Masimo, the key lies in balancing the company’s current
financial challenges with its strong growth potential and market positioning. While
profitability metrics may raise concerns, the robust analyst ratings and significant
potential upside make Masimo a compelling consideration for those willing to take
a long-term view on the healthcare technology sector.

Share on:
